Page 1 of 38
NSG 522 PSYCHOPHARMACOLOGY EXAM 1 — PRACTICE
EXAMINATION COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
PSYCHOPHARMACOLOGY
Prepare effectively for the NSG 522 Psychopharmacology Exam 1 with this focused
study resource. It supports review of essential psychopharmacology concepts,
medication classes, mechanisms of action, therapeutic uses, adverse effects, and
safe medication management. Use the material to reinforce your understanding,
review key topics, and identify areas that may require additional study. This resource
is suited for nursing students, psychiatric-mental health learners, and students
preparing for NSG 522 Psychopharmacology Exam 1.
MULTIPLE CHOICE.
SECTION 1: NEUROPHARMACOLOGY & NEUROTRANSMITTER
FUNDAMENTALS (Questions 1–25)
Question 1: Which of the following correctly describes the four essential
components required for neurotransmission?
A) Receptor, transporter, enzyme, and metabolite
B) Synthesis, storage, release, and receptor binding/inactivation
C) Agonist, antagonist, partial agonist, and inverse agonist
D) Ionotropic, metabotropic, presynaptic, and postsynaptic
Correct Answer: B) Synthesis, storage, release, and receptor
binding/inactivation
Rationale: Neurotransmission requires four essential steps: synthesis of the
neurotransmitter, storage in vesicles, release into the synaptic cleft,
and receptor binding followed by inactivation (reuptake or enzymatic
breakdown).
, Page 2 of 38
Question 2: What is the rate-limiting enzyme in the synthesis of
catecholamines?
A) Aromatic acid decarboxylase
B) Dopamine β-hydroxylase
C) Tyrosine hydroxylase
D) Monoamine oxidase (MAO)
Correct Answer: C) Tyrosine hydroxylase
Rationale: Tyrosine hydroxylase is the rate-limiting enzyme in
catecholamine synthesis. It converts tyrosine to DOPA, and its activity
determines the overall rate of catecholamine production.
Question 3: Which transporter is responsible for loading catecholamines into
synaptic vesicles?
A) Dopamine transporter (DAT)
B) Norepinephrine transporter (NET)
C) Vesicular monoamine transporter (VMAT)
D) Serotonin transporter (SERT)
Correct Answer: C) Vesicular monoamine transporter (VMAT)
Rationale: The vesicular monoamine transporter (VMAT) is responsible for
packaging monoamine neurotransmitters (dopamine, norepinephrine,
serotonin) into synaptic vesicles for storage and release.
Question 4: Reserpine blocks VMAT, leading to which effect?
A) Depletion of catecholamines from synaptic vesicles
B) Increased release of catecholamines
C) Activation of dopamine receptors
D) Enhanced reuptake of catecholamines
Correct Answer: A) Depletion of catecholamines from synaptic vesicles
Rationale: Reserpine blocks the vesicular monoamine transporter (VMAT) ,
preventing the storage of catecholamines in vesicles. This leads to depletion
of catecholamines and causes extreme sedation that can be reversed by
DOPA.
, Page 3 of 38
Question 5: Catecholamines are inactivated through which mechanisms?
A) Reuptake by transporters and metabolic breakdown by COMT and MAO
B) Receptor internalization and degradation
C) Diffusion across the synaptic cleft
D) Binding to autoreceptors only
Correct Answer: A) Reuptake by transporters and metabolic breakdown by
COMT and MAO
Rationale: Catecholamines are inactivated through reuptake by dopamine
or norepinephrine transporters and metabolic breakdown by catechol-O-
methyltransferase (COMT) and monoamine oxidase (MAO) .
Question 6: What is MPTP, and why is it significant in psychopharmacology?
A) A dopamine agonist used to treat Parkinson's disease
B) A neurotoxin that causes symptoms of Parkinson's disease by
damaging substantia nigra neurons
C) A serotonin reuptake inhibitor used as an antidepressant
D) A GABA receptor antagonist
Correct Answer: B) A neurotoxin that causes symptoms of Parkinson's
disease by damaging substantia nigra neurons
Rationale: MPTP is a neurotoxin that selectively destroys dopamine neurons
in the substantia nigra, causing symptoms of Parkinson's disease. It was
discovered when drug users developed parkinsonism after using
contaminated synthetic heroin.
Question 7: The nigrostriatal pathway originates in which brain region?
A) Ventral tegmental area (VTA)
B) Substantia nigra
C) Nucleus accumbens
D) Prefrontal cortex
, Page 4 of 38
Correct Answer: B) Substantia nigra
Rationale: The nigrostriatal pathway originates in the substantia nigra and
projects to the caudate-putamen (striatum). It plays an important role in the
control of movement.
Question 8: Parkinson's disease results from damage to which pathway?
A) Mesolimbic pathway
B) Mesocortical pathway
C) Nigrostriatal pathway
D) Tuberoinfundibular pathway
Correct Answer: C) Nigrostriatal pathway
Rationale: Parkinson's disease is a neurodegenerative disease caused
by damage to the nigrostriatal pathway, specifically the loss of dopamine-
producing cells in the substantia nigra.
Question 9: Which dopamine pathway originates in the ventral tegmental
area (VTA) and projects to the nucleus accumbens?
A) Nigrostriatal pathway
B) Mesolimbic pathway
C) Mesocortical pathway
D) Tuberoinfundibular pathway
Correct Answer: B) Mesolimbic pathway
Rationale: The mesolimbic pathway originates in the ventral tegmental
area (VTA) and projects to the nucleus accumbens and olfactory nucleus. It is
involved in reward, motivation, and drug abuse.
Question 10: Which dopamine pathway is involved in drug abuse and
addiction?
A) Nigrostriatal pathway
B) Mesolimbic and mesocortical pathways
NSG 522 PSYCHOPHARMACOLOGY EXAM 1 — PRACTICE
EXAMINATION COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
PSYCHOPHARMACOLOGY
Prepare effectively for the NSG 522 Psychopharmacology Exam 1 with this focused
study resource. It supports review of essential psychopharmacology concepts,
medication classes, mechanisms of action, therapeutic uses, adverse effects, and
safe medication management. Use the material to reinforce your understanding,
review key topics, and identify areas that may require additional study. This resource
is suited for nursing students, psychiatric-mental health learners, and students
preparing for NSG 522 Psychopharmacology Exam 1.
MULTIPLE CHOICE.
SECTION 1: NEUROPHARMACOLOGY & NEUROTRANSMITTER
FUNDAMENTALS (Questions 1–25)
Question 1: Which of the following correctly describes the four essential
components required for neurotransmission?
A) Receptor, transporter, enzyme, and metabolite
B) Synthesis, storage, release, and receptor binding/inactivation
C) Agonist, antagonist, partial agonist, and inverse agonist
D) Ionotropic, metabotropic, presynaptic, and postsynaptic
Correct Answer: B) Synthesis, storage, release, and receptor
binding/inactivation
Rationale: Neurotransmission requires four essential steps: synthesis of the
neurotransmitter, storage in vesicles, release into the synaptic cleft,
and receptor binding followed by inactivation (reuptake or enzymatic
breakdown).
, Page 2 of 38
Question 2: What is the rate-limiting enzyme in the synthesis of
catecholamines?
A) Aromatic acid decarboxylase
B) Dopamine β-hydroxylase
C) Tyrosine hydroxylase
D) Monoamine oxidase (MAO)
Correct Answer: C) Tyrosine hydroxylase
Rationale: Tyrosine hydroxylase is the rate-limiting enzyme in
catecholamine synthesis. It converts tyrosine to DOPA, and its activity
determines the overall rate of catecholamine production.
Question 3: Which transporter is responsible for loading catecholamines into
synaptic vesicles?
A) Dopamine transporter (DAT)
B) Norepinephrine transporter (NET)
C) Vesicular monoamine transporter (VMAT)
D) Serotonin transporter (SERT)
Correct Answer: C) Vesicular monoamine transporter (VMAT)
Rationale: The vesicular monoamine transporter (VMAT) is responsible for
packaging monoamine neurotransmitters (dopamine, norepinephrine,
serotonin) into synaptic vesicles for storage and release.
Question 4: Reserpine blocks VMAT, leading to which effect?
A) Depletion of catecholamines from synaptic vesicles
B) Increased release of catecholamines
C) Activation of dopamine receptors
D) Enhanced reuptake of catecholamines
Correct Answer: A) Depletion of catecholamines from synaptic vesicles
Rationale: Reserpine blocks the vesicular monoamine transporter (VMAT) ,
preventing the storage of catecholamines in vesicles. This leads to depletion
of catecholamines and causes extreme sedation that can be reversed by
DOPA.
, Page 3 of 38
Question 5: Catecholamines are inactivated through which mechanisms?
A) Reuptake by transporters and metabolic breakdown by COMT and MAO
B) Receptor internalization and degradation
C) Diffusion across the synaptic cleft
D) Binding to autoreceptors only
Correct Answer: A) Reuptake by transporters and metabolic breakdown by
COMT and MAO
Rationale: Catecholamines are inactivated through reuptake by dopamine
or norepinephrine transporters and metabolic breakdown by catechol-O-
methyltransferase (COMT) and monoamine oxidase (MAO) .
Question 6: What is MPTP, and why is it significant in psychopharmacology?
A) A dopamine agonist used to treat Parkinson's disease
B) A neurotoxin that causes symptoms of Parkinson's disease by
damaging substantia nigra neurons
C) A serotonin reuptake inhibitor used as an antidepressant
D) A GABA receptor antagonist
Correct Answer: B) A neurotoxin that causes symptoms of Parkinson's
disease by damaging substantia nigra neurons
Rationale: MPTP is a neurotoxin that selectively destroys dopamine neurons
in the substantia nigra, causing symptoms of Parkinson's disease. It was
discovered when drug users developed parkinsonism after using
contaminated synthetic heroin.
Question 7: The nigrostriatal pathway originates in which brain region?
A) Ventral tegmental area (VTA)
B) Substantia nigra
C) Nucleus accumbens
D) Prefrontal cortex
, Page 4 of 38
Correct Answer: B) Substantia nigra
Rationale: The nigrostriatal pathway originates in the substantia nigra and
projects to the caudate-putamen (striatum). It plays an important role in the
control of movement.
Question 8: Parkinson's disease results from damage to which pathway?
A) Mesolimbic pathway
B) Mesocortical pathway
C) Nigrostriatal pathway
D) Tuberoinfundibular pathway
Correct Answer: C) Nigrostriatal pathway
Rationale: Parkinson's disease is a neurodegenerative disease caused
by damage to the nigrostriatal pathway, specifically the loss of dopamine-
producing cells in the substantia nigra.
Question 9: Which dopamine pathway originates in the ventral tegmental
area (VTA) and projects to the nucleus accumbens?
A) Nigrostriatal pathway
B) Mesolimbic pathway
C) Mesocortical pathway
D) Tuberoinfundibular pathway
Correct Answer: B) Mesolimbic pathway
Rationale: The mesolimbic pathway originates in the ventral tegmental
area (VTA) and projects to the nucleus accumbens and olfactory nucleus. It is
involved in reward, motivation, and drug abuse.
Question 10: Which dopamine pathway is involved in drug abuse and
addiction?
A) Nigrostriatal pathway
B) Mesolimbic and mesocortical pathways
